NeOnc Technologies Holdings Inc. (NTHI) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, NeOnc Technologies Holdings Inc. (NASDAQ: NTHI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.07 (-5.83% 1D, market cap $97.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NTHI ranks #765 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NTHI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NRXP (NRX Pharmaceuticals Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $98.3M) and ORGO (Organogenesis Holdings Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC 17.1%, cap $98.8M). Among the 5-stock peer group, NTHI leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).
Per NTHI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001979414), NeOnc Technologies Holdings Inc. generated $40.0K in revenue (-51.8% YoY), -$62.1M in net income, and -$20.4M in free cash flow against $2.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While NTHI currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.42) and Max Pain ($3.22) forces dealer call-delta covering toward $12.60.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
NeOnc Technologies Holdings Inc. (NTHI) dropped -5.83% to $3.07, trading at 6% of its 52-week range ($2.5 – $12). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
TradingView report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) ("NeOnc" or the "Company"), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that
Gainers Bolt Biotherapeutics (NASDAQ:BOLT) shares moved upwards by 58.8% to $6.65 during Friday's regular session. The market value of their outstanding shares is at $7.9 million. Lucid Diagnostics (NASDAQ:LUCD)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -51.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NTHI today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NTHI. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, NeOnc Technologies Holdings Inc. (NTHI) ranks #765 by composite RQD confidence (31/100, grade E) and #657 by equity capitalization ($97.0M). Within this direct 5-issuer industry benchmark cohort, NTHI leads on earnings valuation at N/A trailing P/E, while ORGO leads on capital efficiency and profitability with 17.1% ROIC and — gross margin. PMVP currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with NTHI at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NTHI
ACTIVE
NeOnc Technologies Holdings Inc. | E | 31/100 | — | — | -35.0% | -5.83% | $97.0M | Benchmark Subject |
| NRXP NRX Pharmaceuticals Inc. | E | 25/100 | — | 58.8% | -35.0% | -4.40% | $98.3M | /nrxp-vs-nthi → |
| ORGO Organogenesis Holdings Inc. (Class A) | E | 34/100 | — | — | 17.1% | -1.64% | $98.8M | /orgo-vs-nthi → |
| PMVP PMV Pharmaceuticals Inc. | D- | 42/100 | — | — | -35.0% | +4.58% | $98.9M | /pmvp-vs-nthi → |
| VTVT vTv Therapeutics Inc. (Class A) | E | 24/100 | — | — | -35.0% | -4.05% | $99.5M | /vtvt-vs-nthi → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), NeOnc Technologies Holdings Inc. (NTHI) reported GAAP revenue of $40.0K (-51.8% vs. FY2024 revenue of $83.0K ) , GAAP net income of -$62.1M, operating cash flow of -$20.4M, and free cash flow of -$20.4M (-383.3% YoY). On the balance sheet, NTHI closed FY2025 with $2.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $40.0K | -$62.1M | -$20.4M | -$20.4M | $2.8M | — |
| FY2024 (FY) | 2024-12-31 | $83.0K | -$11.9M | -$4.2M | -$4.2M | $3.4M | — |
As of 2026-11-03, NeOnc Technologies Holdings Inc. (NASDAQ: NTHI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.07 (-5.83% 1D, market cap $97.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 7/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NTHI ranks #765 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NTHI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NRXP (NRX Pharmaceuticals Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $98.3M) and ORGO (Organogenesis Holdings Inc. (Class A)) posts a E grade (34/100 RQD, P/E N/A, ROIC 17.1%, cap $98.8M). Among the 5-stock peer group, NTHI leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).
Per NTHI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001979414), NeOnc Technologies Holdings Inc. generated $40.0K in revenue (-51.8% YoY), -$62.1M in net income, and -$20.4M in free cash flow against $2.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
NTHI last traded at $3.07 (-5.83% on volume of 93,905 shares), positioning the stock -10.23% below its 50-day simple moving average ($3.42) and -43.25% below its 200-day simple moving average ($5.41). Across its 52-week range of $2.50 to $12.00, NTHI sits at the 6.0% percentile with a 14-day RSI of 54.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.69 to $3.45).
NeOnc Technologies Holdings Inc. (NTHI) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $3.07 (-5.83% 1D, market capitalization $97.0M).
NeOnc Technologies Holdings Inc. (NTHI) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..1B. Revenue, customer base, and product details are — The reported revenue of — for FY 2025 and $0.1M for FY 2024 indicates minimal top-line activity .
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), NeOnc Technologies Holdings Inc. (NTHI) reported $40.0K in annual revenue (up from $83.0K in FY2024, -51.8% YoY) and -$62.1M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($83.0K revenue, -$11.9M net income) through FY2025, NTHI scaled operating cash flow to -$20.4M and free cash flow to -$20.4M, backed by $2.8M in total assets against $0 in total debt.
The supply chain is NONE, with no upstream or downstream links and no proprietary signals recorded.
Real-time company headlines, analyst actions, and sector developments for NeOnc Technologies Holdings Inc. (NTHI) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
TradingView report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering NeOnc Technologies Holdings Inc. (NTHI) market action, institutional positioning, and fundamental catalysts.
Don't sleep on NTHI's setup in Health Care. Shares trade near the lower-middle of their 52-week range with a Beta of 1.0 and a 2.97% gain on the day, while the company has disclosed clinical data readouts including a 48.9% six-month progression-free rate.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (31/100) backs up the fundamental quality.
@DeepValue_CFA Agree on the RQD 31/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.26 and keeping dry powder in case we test $3.03.
Here is the bear case nobody on the bull side wants to address on NTHI: Operating losses widened to -$58.2M in FY 2025 with ROIC at -35%, FCF yield at -21.93%, cash of only $0.1M, and an Insider Conviction pillar score of 3/20.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: